Machine learning methods for prediction of CDK-inhibitors

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Ramana, Jayashree ^a   Gupta, Dinesh ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR;

ACCURACY; ARTICLE; ARTIFICIAL NEURAL NETWORK; CLASSIFICATION ALGORITHM; CONTROLLED STUDY; DRUG DETERMINATION; EVOLUTIONARY ALGORITHM; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; PREDICTION; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SUPPORT VECTOR MACHINE; VALIDATION PROCESS; ARTIFICIAL INTELLIGENCE; DRUG ANTAGONISM; INTERNET; VALIDATION STUDY;

ARTIFICIAL INTELLIGENCE; CYCLIN-DEPENDENT KINASES; INTERNET; PROTEIN KINASE INHIBITORS; ROC CURVE;

EID: 78149442889     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013357     Document Type: Article

References (40)

1. Hochegger H, Takeda S, Hunt T (2008) Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol 9: 910-916.
2. De Vivo M, Cavalli A, Bottegoni G, Carloni P, Recanatini M (2006) Role of phosphorylated Thr160 for the activation of the CDK2/Cyclin A complex. Proteins: Structure, Function, and Bioinformatics 62: 89-98.
3. Besson A, Dowdy SF, Roberts JM (2008) CDK Inhibitors: Cell Cycle Regulators and Beyond. Developmental Cell 14: 159-169.
4. Larson P, Schlechter B, King C-L, Yang Q, Glass C, et al. (2008) CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 8: 68.
5. Liang H, Li J, Tian D (2008) Expression and clinical implication of p27 and p57 in cutaneous squamous cell carcinoma and Bowen's disease. The Chinese- German Journal of Clinical Oncology 7: 176-178.
6. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, et al. (1995) p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes & Development 9: 650-662.
7. Poole AJ, Heap D, Carroll RE, Tyner AL (2004) Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon. Oncogene 23: 8128-8134.
8. Agarwal SK, Mateo CM, Marx SJ (2009) Rare Germline Mutations in Cyclin- Dependent Kinase Inhibitor Genes in Multiple Endocrine Neoplasia Type 1 and Related States. J Clin Endocrinol Metab 94: 1826-1834.
9. Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, et al. (2008) Down-regulation of p57Kip2 Induces Prostate Cancer in the Mouse. Cancer Res 68: 3601-3608.
10. Joshua NA, Kevin JL (2002) Intrinsic structural disorder and sequence features of the cell cycle inhibitor p57Kip2. Proteins: Structure, Function, and Genetics 46: 1-7.
11. Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, et al. (2009) Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proceedings of the National Academy of Sciences 106: 12968-12973.
12. Nozato T, Ito H, Watanabe M, Ono Y, Adachi S, et al. (2001) Overexpression of cdk Inhibitor p16INK4aby Adenovirus Vector Inhibits Cardiac Hypertrophy in vitro and in vivo: a Novel Strategy for the Gene Therapy of Cardiac Hypertrophy. Journal of Molecular and Cellular Cardiology 33: 1493-1504.
13. Fischer PM, Lane DP (2000) Inhibitors of Cyclin-Dependent Kinases as Anti- Cancer Therapeutics. Current Medicinal Chemistry 7: 1213-1245.
14. Fischer PM, Gianella-Borradori A (2003) CDK inhibitors in clinical development for the treatment of cancer. Expert Opinion on Investigational Drugs 12: 955-970.
15. McInnes C (2008) Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug Discovery Today 13: 875-881.
16. Guendel I, Agbottah E, Kehn-Hall K, Kashanchi F (2010) Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Research and Therapy 7: 7.
17. Geyer JA, Prigge ST, Waters NC (2005) Targeting malaria with specific CDK inhibitors. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1754: 160-170.
18. Grant KM, Dunion MH, Yardley V, Skaltsounis A-L, Marko D, et al. (2004) Inhibitors of Leishmania mexicana CRK3 Cyclin-Dependent Kinase: Chemical Library Screen and Antileishmanial Activity. Antimicrob Agents Chemother 48: 3033-3042.
19. Naula C, Parsons M, Mottram JC (2005) Protein kinases as drug targets in trypanosomes and Leishmania. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1754: 151-159.
20. Boyer MJ, Cheng T (2007) The CDK inhibitors: potential targets for therapeutic stem cell manipulations? Gene Ther 15: 117-125.
21. Cánepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, et al. (2007) INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 59: 419-426.
22. Kei-ichi N, Keiko N (1998) Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. BioEssays 20: 1020-1029.
23. Wysocki R, Javaheri A, Kristjansdottir K, Sha F, Kron SJ (2006) CDK Pho85 targets CDK inhibitor Sic1 to relieve yeast G1 checkpoint arrest after DNA damage. Nat Struct Mol Biol 13: 908-914.
24. Churchman ML, Brown ML, Kato N, Kirik V, Hulskamp M, et al. (2006) SIAMESE, a Plant-Specific Cell Cycle Regulator, Controls Endoreplication Onset in Arabidopsis thaliana. Plant Cell 18: 3145-3157.
25. Le Foll M, Blanchet S, Millan L, Mathieu C, Bergounioux C, et al. (2008) The plant CDK inhibitor NtKIS1a interferes with dedifferentiation, is specifically down regulated during development and interacts with a JAB1 homolog. Plant Science 175: 513-523.
26. Finn RD, Mistry J, Tate J, Coggill P, Heger A, et al. The Pfam protein families database. Nucleic Acids Research 38: D211-D222.
27. Ramana J, Gupta D (2009) LipocalinPred: a SVM-based method for prediction of lipocalins. BMC Bioinformatics 10: 445.
28. Kumar M, Gromiha MM, Raghava GPS (2008) Prediction of RNA binding sites in a protein using SVM and PSSM profile. Proteins: Structure, Function, and Bioinformatics 71: 189-194.
29. Rumelhart DE, McClelland JL (1986) Parallel Distributed Processing: MIT Press. 567 p.
30. Hannon GJ, Casso D, Beach D (1994) KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. Proceedings of the National Academy of Sciences of the United States of America 91: 1731-1735.
31. Gyuris J, Golemis E, Chertkov H, Brent R (1993) Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75: 791-803.
32. Poon RYC, Hunter T (1995) Dephosphorylation of Cdk2 Thr160 by the Cyclin- Dependent Kinase-Interacting Phosphatase KAP in the Absence of Cyclin. Science 270: 90-93.
33. Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240: 1285-1293.
34. Kalita MK, Nandal UK, Pattnaik A, Sivalingam A, Ramasamy G, et al. (2008) CyclinPred: A SVM-Based Method for Predicting Cyclin Protein Sequences. PLoS ONE 3: e2605.
35. Chang EJ, Begum R, Chait BT, Gaasterland T (2007) Prediction of Cyclin- Dependent Kinase Phosphorylation Substrates. PLoS ONE 2: e656.
36. Li W, Godzik A (2006) Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 22: 1658-1659.
37. Vapnik NV (1998) Statistical Learning Theory. New York: Wiley-Interscience. 740 p.
38. Joachims T (1999) Making large-Scale SVM Learning Practical. In: Schölkopf B, Burges C, Smola A, eds. Advances in Kernel Methods - Support Vector Learning: MIT-Press. pp 169-184.
39. Hertz J, Krogh A, Palmer GR (1991) Introduction to the theory of neural computation: Addison-Wesley Longman Publishing Co., Inc. 327 p.
40. Fawcett T (2006) An introduction to ROC analysis. Pattern Recogn Lett 27: 861-874.